6-Month Adjuvant Chemotherapy Superior to 3-Month Adjuvant Chemotherapy in Stage III Colon Cancer

Share this content:
Evidence from previous studies have shown that the legacy standard of 12-month fluoropyrimidine-based therapy could be reduced to 6 months, and perhaps even further to 3 months.
Evidence from previous studies have shown that the legacy standard of 12-month fluoropyrimidine-based therapy could be reduced to 6 months, and perhaps even further to 3 months.

Oxaliplatin-based adjuvant chemotherapy for 6 months led to superior outcomes compared with 3 months among patients with stage III colon cancer, according to a study published in the Journal of Clinical Oncology.1

Reducing the duration of chemotherapy without decreasing efficacy, and therefore the incidence of significant toxicities associated with treatment, is one of the primary goals of cancer management. Evidence from previous studies have shown that the legacy standard of 12-month fluoropyrimidine-based therapy could be reduced to 6 months, and perhaps even further to 3 months.

For the phase 3 International Duration Evaluation of Adjuvant Chemotherapy (IDEA) France study (ClinicalTrials.gov Identifier: NCT00958738), researchers randomly assigned 2010 patients with advanced colon cancer to receive 3 months or 6 months of chemotherapy. Ninety-nine percent of patients had stage III colon cancer, of whom 75% and 25% had N1 and N2 disease, respectively, and 90% of patients received mFOLFOX6 and 10% were treated with CAPOX.

Overall, 94% of patients receiving treatment for 3 months and 78% of patients receiving treatment for 6 months completed treatment. There were 578 disease-free survival events; 314 in the 3-month arm and 264 in the 6-month arm.

After a median follow-up of 4.3 years, results showed that patients in the 3-month arm and 6-month arm had 3-year disease-free survival (DFS) rates of 72% and 76%, respectively (hazard ratio [HR], 1.24; 95% CI, 1.05-1.46; P = .0112).

For patients who received mFOLFOX6, the 3-year DFS rate was 72% in the 3-month arm compared with 76.3% in the 6-month arm (HR, 1.27; 95% CI, 1.07-1.51). For patients with T4 and/or N2 disease the 3-year DFS rate was 58% and 66% respectively. For patients with T1-3N1 disease, the 3-year DFS rate was 81% and 83%, respectively.

The rates of maximal grade 2 or 3 neuropathy was 28% and 8%, respectively, among patients in the 3-month arm, and 41% and 25% in the 6-month arm (P < .001). The final rates of residual neuropathy that were worse than grade 1 was 3% and 7% in the 3- and 6-month arms, respectively.

The authors concluded that evidence from the study “shows superiority of 6 months of adjuvant chemotherapy compared with 3 months, especially in the T4 and/or N2 subgroups. These results should be considered alongside the international IDEA collaboration data.”

Reference

  1. Andre T, Vernerey D, Mineur L, et al. 3 Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial [published online April 5, 2018]. J Clin Oncol. doi: 10.1200/JCO.2017.76.0355

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs